Press Release: Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea | Cannabis Law Report | How to buy Skittles Moonrock online
Learn how to order CBD Vape online. TOP QUALITY GRADE A++
Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.
👉 Click here to Visit our shop! 🛒
Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea’s official patent and intellectual property authority. The patent covers the Company’s innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings.
Further research was conducted in rats to assess whether MEAI’s effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards such as sucrose. This finding suggests that MEAI’s impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions.
This pioneering research has led to multiple patent applications in the U.S. and other global jurisdictions and is part of Clearmind’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders. The collaboration aims to combine Clearmind’s MEAI, a novel proprietary psychedelic treatment for addiction and mental health, with SciSparc’s PEA.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
Leave a Reply
Want to join the discussion?Feel free to contribute!